Comparison of clinicopathologic features between cases of PCFCL and SCFL
| . | PCFCL, n (%) . | SCFL, n (%) . | P* . |
|---|---|---|---|
| n | 30 | 10 | |
| Sex | |||
| Female | 13 (43) | 5 (50) | .73 |
| Male | 17 (57) | 5 (50) | |
| Age, median (range) | 60 (32-79) | 59 (33-91) | .47 |
| Staging | |||
| IA (cutaneous) | 30 (100) | 0 | <.001 |
| II-IV | 0 (0) | 10 (100) | |
| Tumor Site | |||
| Head and neck | 15 (50) | 6 (60) | .87 |
| Trunk | 12 (40) | 3 (30) | |
| Extremity (leg/arm) | 3 (10) | 1 (10) | |
| Therapy† | |||
| Localized only | 25 (83) | 5 (50) | .09 |
| Systemic | 5 (17) | 5 (50) | |
| Follow-up, mo | 79 | 55 | |
| Recurrence rate | 17/30 (57) | 9/10 (90) | |
| Time to recur, median, mo | 13 | 15 | |
| Recurrence | |||
| Same cutaneous site | 13/17 (76) | N/A | |
| Different cutaneous site | 1/17 (6) | N/A | |
| Extracutaneous Site | 4/17 (24) | N/A | |
| Histology | |||
| Nodular and nodular/diffuse | 22/28 (79) | 8/8 (100) | .30 |
| Diffuse | 6/28 (21) | 0/8 (0) | |
| IHC | |||
| CD10 | |||
| Negative | 6 (29) | 1 (12) | .63 |
| Positive | 15 (71) | 7 (88) | |
| BCL2 | |||
| Negative | 22 (73) | 1 (10) | <.001 |
| Positive | 8 (27) | 9 (90) | |
| CD21 | |||
| <30% | 10 (33) | 0 (0) | .07 |
| ≥30% | 17 (57) | 8 (100) | |
| Ki-67 | |||
| <30% | 6 (25) | 8 (80) | .006 |
| ≥30% | 18 (75) | 2 (20) | |
| Gene rearrangements | |||
| BCL2 | |||
| Negative | 25 (83) | 0 (0) | <.001 |
| Positive | 5 (17) | 9 (100) | |
| BCL6 | |||
| Negative | 27 (96) | 2 (100) | .99 |
| Positive | 1 (4) | 0 (0) |
| . | PCFCL, n (%) . | SCFL, n (%) . | P* . |
|---|---|---|---|
| n | 30 | 10 | |
| Sex | |||
| Female | 13 (43) | 5 (50) | .73 |
| Male | 17 (57) | 5 (50) | |
| Age, median (range) | 60 (32-79) | 59 (33-91) | .47 |
| Staging | |||
| IA (cutaneous) | 30 (100) | 0 | <.001 |
| II-IV | 0 (0) | 10 (100) | |
| Tumor Site | |||
| Head and neck | 15 (50) | 6 (60) | .87 |
| Trunk | 12 (40) | 3 (30) | |
| Extremity (leg/arm) | 3 (10) | 1 (10) | |
| Therapy† | |||
| Localized only | 25 (83) | 5 (50) | .09 |
| Systemic | 5 (17) | 5 (50) | |
| Follow-up, mo | 79 | 55 | |
| Recurrence rate | 17/30 (57) | 9/10 (90) | |
| Time to recur, median, mo | 13 | 15 | |
| Recurrence | |||
| Same cutaneous site | 13/17 (76) | N/A | |
| Different cutaneous site | 1/17 (6) | N/A | |
| Extracutaneous Site | 4/17 (24) | N/A | |
| Histology | |||
| Nodular and nodular/diffuse | 22/28 (79) | 8/8 (100) | .30 |
| Diffuse | 6/28 (21) | 0/8 (0) | |
| IHC | |||
| CD10 | |||
| Negative | 6 (29) | 1 (12) | .63 |
| Positive | 15 (71) | 7 (88) | |
| BCL2 | |||
| Negative | 22 (73) | 1 (10) | <.001 |
| Positive | 8 (27) | 9 (90) | |
| CD21 | |||
| <30% | 10 (33) | 0 (0) | .07 |
| ≥30% | 17 (57) | 8 (100) | |
| Ki-67 | |||
| <30% | 6 (25) | 8 (80) | .006 |
| ≥30% | 18 (75) | 2 (20) | |
| Gene rearrangements | |||
| BCL2 | |||
| Negative | 25 (83) | 0 (0) | <.001 |
| Positive | 5 (17) | 9 (100) | |
| BCL6 | |||
| Negative | 27 (96) | 2 (100) | .99 |
| Positive | 1 (4) | 0 (0) |